Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy
Publication Date: August 2, 2022
Last Updated: August 4, 2022
Summary of Recommendations
For patients with CRC being considered for immune checkpoint inhibitor therapy, pathologists should use MMR-IHC and/or MSI by PCR for the detection of DNA MMR defects. Although MMR-IHC or MSI by PCR are preferred, pathologists may use a validated MSI by NGS assay for the detection of DNA MMR defects. (S)
Note: MSI by NGS assay must be validated against MMR-IHC or MSI by PCR and must show equivalency.
324662
Title
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy
Authoring Organization
College of American Pathologists